Literature DB >> 34610896

Should non-invasive diffuse main-duct intraductal papillary mucinous neoplasms be treated with total pancreatectomy?

Alex B Blair1, Ross M Beckman1, Joseph R Habib1, James F Griffin1, Kelly Lafaro1, Richard A Burkhart1, William Burns1, Matthew J Weiss2, John L Cameron1, Christopher L Wolfgang3, Jin He4.   

Abstract

BACKGROUND: Main-duct (MD) intraductal papillary mucinous neoplasm (IPMN) is associated with malignancy risk. There is a lack of consensus on treatment (partial or total pancreatectomy) when the MD is diffusely involved. We sought to characterize the pancreatic remnant fate after partial pancreatectomy for non-invasive diffuse MD-IPMN.
METHODS: Consecutive patients with partial pancreatectomy for non-invasive MD-IPMN from 2004 to 2016 were analyzed. Diffuse MD-IPMN was defined by preoperative imaging as dilation of the MD in the head of the pancreas more than 5 mm and involving the whole gland.
RESULTS: Of 127 patients with resected non-invasive MD-IPMN, 47 (37%) had diffuse MD involvement. Eleven of 47(23%) patients developed imaging evidence of progression or new cystic disease in the pancreatic remnant. Patients with diffuse MD-IPMN were older (73yrs vs 67yrs, p = 0.009), more likely to receive a pancreaticoduodenectomy (96% vs 56%, p < 0.001) and have high-grade dysplasia (51% vs 31%, p = 0.025) than those with focal MD involvement. Diffuse MD involvement was not associated with shorter PFS following partial pancreatectomy (p = 0.613).
CONCLUSION: Partial pancreatectomy is an appropriate surgical approach for diffuse MD-IPMN, and is not associated with earlier progression after surgery as compared to partial pancreatectomy for focal dilation.
Copyright © 2021 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34610896      PMCID: PMC8940727          DOI: 10.1016/j.hpb.2021.09.013

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.842


  31 in total

1.  Clinicopathologic characteristics of patients with resected multifocal intraductal papillary mucinous neoplasm of the pancreas.

Authors:  Stefan Fritz; Moritz Schirren; Miriam Klauss; Frank Bergmann; Thilo Hackert; Werner Hartwig; Oliver Strobel; Lars Grenacher; Markus W Büchler; Jens Werner
Journal:  Surgery       Date:  2012-07-06       Impact factor: 3.982

2.  A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas.

Authors:  Olca Basturk; Seung-Mo Hong; Laura D Wood; N Volkan Adsay; Jorge Albores-Saavedra; Andrew V Biankin; Lodewijk A A Brosens; Noriyoshi Fukushima; Michael Goggins; Ralph H Hruban; Yo Kato; David S Klimstra; Günter Klöppel; Alyssa Krasinskas; Daniel S Longnecker; Hanno Matthaei; G Johan A Offerhaus; Michio Shimizu; Kyoichi Takaori; Benoit Terris; Shinichi Yachida; Irene Esposito; Toru Furukawa
Journal:  Am J Surg Pathol       Date:  2015-12       Impact factor: 6.394

Review 3.  Intraductal papillary mucinous neoplasms (IPMNs): is it time to (sometimes) spare the knife?

Authors:  Claudio Bassi; Stefano Crippa; Roberto Salvia
Journal:  Gut       Date:  2008-03       Impact factor: 23.059

Review 4.  Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas.

Authors:  Masao Tanaka; Carlos Fernández-Del Castillo; Terumi Kamisawa; Jin Young Jang; Philippe Levy; Takao Ohtsuka; Roberto Salvia; Yasuhiro Shimizu; Minoru Tada; Christopher L Wolfgang
Journal:  Pancreatology       Date:  2017-07-13       Impact factor: 3.996

5.  Prognostic impact of pancreatic margin status in the intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Tsutomu Fujii; Koichi Kato; Yasuhiro Kodera; Mitsuro Kanda; Shunji Nagai; Suguru Yamada; Akiyuki Kanzaki; Hiroyuki Sugimoto; Shuji Nomoto; Shin Takeda; Satoshi Morita; Shigeo Nakamura; Akimasa Nakao
Journal:  Surgery       Date:  2010-08       Impact factor: 3.982

Review 6.  The Clinical Management of Main Duct Intraductal Papillary Mucinous Neoplasm of the Pancreas.

Authors:  Chiara Dal Borgo; Giampaolo Perri; Alex Borin; Giovanni Marchegiani; Roberto Salvia; Claudio Bassi
Journal:  Dig Surg       Date:  2018-02-08       Impact factor: 2.588

Review 7.  Comparative Effectiveness of Resection vs Surveillance for Pancreatic Branch Duct Intraductal Papillary Mucinous Neoplasms With Worrisome Features.

Authors:  Yinin Hu; Lily E. Johnston; Vanessa M. Shami; Todd W. Bauer; Reid B. Adams; George J. Stukenborg; Victor M. Zaydfudim
Journal:  JAMA Surg       Date:  2018-03-01       Impact factor: 14.766

8.  MR cholangiopancreatographic differentiation of benign and malignant intraductal mucin-producing tumors of the pancreas.

Authors:  H Irie; H Honda; H Aibe; T Kuroiwa; K Yoshimitsu; K Shinozaki; K Yamaguchi; M Shimada; K Masuda
Journal:  AJR Am J Roentgenol       Date:  2000-05       Impact factor: 3.959

9.  The Dilemma of the Dilated Main Pancreatic Duct in the Distal Pancreatic Remnant After Proximal Pancreatectomy for IPMN.

Authors:  Rachel E Simpson; Eugene P Ceppa; Howard H Wu; Fatih Akisik; Michael G House; Nicholas J Zyromski; Attila Nakeeb; Mohammad A Al-Haddad; John M DeWitt; Stuart Sherman; C Max Schmidt
Journal:  J Gastrointest Surg       Date:  2019-01-02       Impact factor: 3.452

10.  Survival Analysis and Risk for Progression of Intraductal Papillary Mucinous Neoplasia of the Pancreas (IPMN) Under Surveillance: A Single-Institution Experience.

Authors:  Marco Del Chiaro; Zeeshan Ateeb; Marcus Reuterwall Hansson; Elena Rangelova; Ralf Segersvärd; Nikolaos Kartalis; Christoph Ansorge; Matthias J Löhr; Urban Arnelo; Caroline Verbeke
Journal:  Ann Surg Oncol       Date:  2016-11-07       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.